- Skin care product company Integumen said it was in a number of discussions about acquisitions and revenue-share collaborations.

The company said it was confirming the talks after noting an increase in its share price over recent days.

'The transformation of the company has been swift since new management took over in August 2018,' Integumen said.

'This is evident from the content of trading updates, recent laboratory expansion and CBD test results from the company's Labskin Eco-System.'

'Part of Integumen's growth strategy involves actively pursuing a broader portfolio of services, that contribute to increased revenues per client, through existing revenue shared collaboration and acquisition options that include, data analytics, software and biophysics integration services.'

'The company is currently involved in a number of such discussions that may or may not lead to further accelerated expansion of the company portfolio.'

'Integumen will update the market with any new material information as appropriate in line with regulatory disclosure requirements.'

At 1:36pm: [LON:SKIN] Integumen Plc Ord 1p share price was +0.1p at 2.17p

Story provided by